P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

8-2023

Volume

7

Issue

3

Published In/Presented At

https://doi.org/10.1097/01.HS9.0000970368.33859.48

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article